International โบ United States ยท Last reviewed 2026-05-16
United States
Summary
In the United States, medical treatment of minors with gender dysphoria is covered by guidelines of the Endocrine Society (2017), the American Academy of Pediatrics (AAP, policy statement 2018) and WPATH (SOC-8, 2022). As of June 2025, 27 states had enacted bans on gender-affirming care for minors; on 18 June 2025 the Supreme Court ruled 6โ3 in United States v. Skrmetti that Tennessee's ban does not violate the Equal Protection Clause (source).
1. Clinical guidelines
- Endocrine Society Clinical Practice Guideline (2017) โ on endocrine treatment of gender-dysphoric/gender-incongruent persons (source). According to the Cass Review, early versions of this guideline (2009) and WPATH SOC-7 influenced nearly all other guidelines (source).1
- AAP Policy Statement (2018, Rafferty et al.).2
- WPATH SOC-8 (2022) โ see WPATH SOC and the Dutch Protocol.
2. State legislation
As of June 2025, 27 US states had enacted bans on gender-affirming care for minors; after the Skrmetti ruling, 25 of those bans remain in effect, while the bans in Montana and Arkansas are blocked by courts (source). Court cases are discussed under /debate/legal-cases/.3
3. Florida AHCA review 2022
The Florida Agency for Health Care Administration published a report on 2 June 2022 concluding that puberty blockers, hormone therapy and sex reassignment surgery are "not consistent with generally accepted professional medical standards and are experimental and investigational", and that the research is insufficient to demonstrate efficacy and safety; the agency then started rulemaking on Medicaid coverage (source). See /evaluations/florida-aapcs-review/.
4. United States v Skrmetti (Supreme Court 2024โ2025)
The US Supreme Court heard arguments on 4 December 2024 in United States v. Skrmetti, a review of the Tennessee law (SB1) that bans puberty blockers and hormones for minors with gender dysphoria. On 18 June 2025 the Court ruled 6โ3 that the law does not violate the Equal Protection Clause: it classifies by age and medical diagnosis, not sex, and satisfies rational basis review (source). See /debate/legal-cases/.4
See also
- Central US evaluation: Florida AHCA review 2022
- WPATH context: WPATH SOC, WPATH Files
- Legal context: Bell v Tavistock, US v Skrmetti
- Critics of American guidelines: Levine et al.
- Worldwide overview: Status 2025
- International comparison โ US alongside other countries in table.
- Timeline โ policy decisions chronologically.
- FAQ ยท Glossary.
Footnotes
- Hembree WC, et al. J Clin Endocrinol Metab. 2017;102(11):3869โ903.
- Rafferty J. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018;142(4):e20182162.
- KFF. What are the implications of the Skrmetti ruling for minors' access to gender-affirming care? June 2025.
- United States v. Skrmetti, No. 23-477 (oral arguments 4 December 2024; decided 18 June 2025).
- Block J. Dispute arises over World Professional Association for Transgender Health's involvement in WHO's trans health guideline. BMJ. 2024;387:q2227.